Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 6/20 | 0.39 |
| ▸ | PRKCA | P17252 | 5/20 | 0.39 |
| ▸ | PRKCH | P24723 | 3/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 7/20 | 0.33 |
| ▸ | QPCT | Q16769 | 6/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10038827 | 0.87 | PRKCB (0.43) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3597055 | 0.86 | PRKCB (0.42) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3597076 | 0.85 | PRKCA (0.44) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3602481 | 0.83 | PRKCB (0.40) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3602484 | 0.74 | PRKCB (0.40) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL12004375 | 0.72 | PRKCB (0.44) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL9374514 | 0.70 | PRKCB (0.57) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3540477 | 0.65 | PRKCB (0.76) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL9084418 | 0.64 | PRKCB (0.72) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3582396 | 0.62 | PRKCB (0.60) | PRKCBPRKCAPRKCHPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-4652269-A | Process for the continuous trichromatic dyeing of synthetic polyamide materials: including a blue anthraquinone reactive dye | CIBA-GEIGY CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| US-4514187-A | DISULFO-CONTAINING ANTHRAQUINONE DYES, ACID DYES, MIXTURES | CIBA-GEIGY CORPORATION (US) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | DHFR, RORA, CYP2A6 | PRKCB 4422/4885PRKCA 4167/4885PRKCH 4117/4885 |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | PRKCB 2976/4885PRKCA 3364/4885PRKCH 3124/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | PRKCB 3873/4885PRKCA 4215/4885PRKCH 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.